Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capsaicin dermal patch - Grunenthal

Drug Profile

Capsaicin dermal patch - Grunenthal

Alternative Names: 8% capsaicin patch - NeurogesX; Capsaicin; NGX-4010; Qutenza; Transacin; Transdolor™ Pain Treatment System

Latest Information Update: 23 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeurogesX
  • Developer Astellas Pharma Europe Ltd; NeurogesX
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action GABA A receptor modulators; Melatonin receptor modulators; Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • Registered Diabetic neuropathies
  • No development reported Postoperative pain

Most Recent Events

  • 19 Mar 2019 Grunenthal initiates enrolment in the phase III CAPTRANE trial for Neuropathic pain in France (NCT03794388)
  • 14 Nov 2018 Capsaicin dermal patch licensed to Averitas Pharma in USA
  • 05 Nov 2018 Capsaicin dermal patch is available for licensing in Asia, Australia as of 05 Nov 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top